Our findings are consistent with the survival data showing that both luminal A and TNBC breast cancer patients with CREB3L1-low tumors have a significantly worse prognosis, as compared to similar patients with CREB3L1-high tumors [13]. This evidence concerns the gene CREB3L1 and breast cancer.